Combination therapy has been reported to have a better overall response rate (ORR), progression‐free survival (PFS) and overall survival (OS) in patients than monotherapy,1, 2 although there have been some successful reports of crizotinib monotherapy in EGFR‐mutant NSCLC that acquired MET amplification. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.